A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab (FCFD4514S) in Patients With Geographic Atrophy Who Have Completed Genentech-Sponsored Lampalizumab Studies
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2017
At a glance
- Drugs Lampalizumab (Primary)
- Indications Dry age-related macular degeneration
- Focus Adverse reactions
- Sponsors Genentech
- 13 Sep 2017 Planned End Date changed from 30 Jun 2019 to 28 Mar 2022.
- 13 Sep 2017 Planned primary completion date changed from 30 Jun 2019 to 29 Jun 2019.
- 02 May 2017 Planned number of patients changed from 100 to 113.